CATALOGO DEI PRODOTTI DELLA RICERCA

FATTOVICH, Giovanna
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.321
EU - Europa 13.447
AS - Asia 10.677
SA - Sud America 1.191
AF - Africa 173
Continente sconosciuto - Info sul continente non disponibili 12
OC - Oceania 12
Totale 41.833
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.160
SG - Singapore 5.152
RU - Federazione Russa 4.271
GB - Regno Unito 3.743
CN - Cina 3.081
FR - Francia 1.120
BR - Brasile 980
IT - Italia 921
DE - Germania 884
IE - Irlanda 785
VN - Vietnam 719
SE - Svezia 705
HK - Hong Kong 685
FI - Finlandia 568
KR - Corea 403
UA - Ucraina 177
IN - India 135
TR - Turchia 99
CA - Canada 87
AR - Argentina 73
BD - Bangladesh 67
JP - Giappone 56
PL - Polonia 48
NG - Nigeria 43
NL - Olanda 41
MX - Messico 40
IQ - Iraq 39
ES - Italia 35
ID - Indonesia 33
ZA - Sudafrica 33
AT - Austria 29
EC - Ecuador 28
VE - Venezuela 26
PK - Pakistan 25
BE - Belgio 24
PE - Perù 21
TN - Tunisia 21
CO - Colombia 20
CL - Cile 17
UZ - Uzbekistan 17
AE - Emirati Arabi Uniti 16
SA - Arabia Saudita 16
AZ - Azerbaigian 15
KE - Kenya 14
MA - Marocco 14
DZ - Algeria 13
LT - Lituania 13
PY - Paraguay 12
UY - Uruguay 11
IL - Israele 10
JO - Giordania 10
PH - Filippine 10
AU - Australia 9
EG - Egitto 9
EU - Europa 9
MY - Malesia 9
PS - Palestinian Territory 9
SN - Senegal 9
AL - Albania 8
KG - Kirghizistan 8
NP - Nepal 8
BG - Bulgaria 7
GE - Georgia 7
HU - Ungheria 7
OM - Oman 7
PT - Portogallo 7
CZ - Repubblica Ceca 6
DO - Repubblica Dominicana 6
GA - Gabon 6
RO - Romania 6
BH - Bahrain 5
CH - Svizzera 5
GR - Grecia 5
JM - Giamaica 5
LB - Libano 5
LV - Lettonia 5
MD - Moldavia 5
PA - Panama 5
RS - Serbia 5
TH - Thailandia 5
CR - Costa Rica 4
HN - Honduras 4
IR - Iran 4
KZ - Kazakistan 4
NO - Norvegia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
BO - Bolivia 3
ET - Etiopia 3
HR - Croazia 3
NI - Nicaragua 3
NZ - Nuova Zelanda 3
SK - Slovacchia (Repubblica Slovacca) 3
AO - Angola 2
BB - Barbados 2
BN - Brunei Darussalam 2
CY - Cipro 2
EE - Estonia 2
KH - Cambogia 2
KW - Kuwait 2
MM - Myanmar 2
Totale 41.809
Salva come PNG Salva come JPEG
Città #
Southend 2.941
Singapore 2.938
Jacksonville 2.515
Woodbridge 1.526
Chandler 1.414
Ashburn 1.396
San Jose 1.353
Moscow 1.250
Ann Arbor 934
Dallas 932
Houston 834
Dublin 785
Hong Kong 668
The Dalles 521
Verona 448
Wilmington 418
Lawrence 372
Princeton 371
Lancaster 356
Nanjing 303
Beijing 274
Jinan 274
Ho Chi Minh City 263
Sindelfingen 262
Los Angeles 227
New York 225
Shenyang 221
Buffalo 182
Hanoi 171
Kent 149
Hebei 145
Tianjin 127
Changsha 121
Helsinki 120
Zhengzhou 105
Boardman 97
Haikou 91
Milan 91
Nanchang 90
São Paulo 81
Guangzhou 76
Taizhou 75
Redondo Beach 74
Jiaxing 73
Columbus 71
Hangzhou 70
Orem 70
Ningbo 69
Santa Clara 61
Taiyuan 61
Chennai 50
Norwalk 50
Tokyo 50
Washington 47
Seattle 46
Munich 43
Falls Church 42
Lanzhou 41
Abuja 39
Chicago 38
Da Nang 35
Frankfurt am Main 35
Nuremberg 35
Warsaw 32
Council Bluffs 31
San Francisco 31
Brooklyn 29
Philadelphia 29
Rio de Janeiro 29
Amsterdam 28
Stockholm 28
Manchester 27
Haiphong 26
Montreal 25
Seoul 23
Toronto 23
Belo Horizonte 22
Fuzhou 22
Brussels 21
London 21
Rome 21
Atlanta 20
Boston 20
Biên Hòa 19
Turku 19
Auburn Hills 18
Johannesburg 18
Phoenix 18
Falkenstein 17
Tashkent 17
Shanghai 16
Baku 15
Dhaka 15
Lima 15
Brasília 14
Porto Alegre 14
Baghdad 13
Dearborn 13
Fairfield 13
Nairobi 13
Totale 27.617
Salva come PNG Salva come JPEG
Nome #
Accuracy of ultrasound in the detection of liver fibrosis in chronic viral hepatitis. 318
Metodo radioimmunologico ed elettrosineresi nello studio dell'antigene Australia (HBAg) e dell'anticorpo (HBAc). Risultati comparativi 307
A 25 years longitudina study of hepatitis B e antigen positive chornic hepatitis B in italian patients 220
A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone. 211
The homestasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients. 206
A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. 204
Endogenously produced TNF-α contributes to the expression of CXCL10/IP-10 in IFN-λ3-activated plasmacytoid dendritic cells 202
Protease inhibitors-based therapy induces acquired spherocytic-like anemia and ineffective erythropoiesis in chronic HCV patients 196
A randomized controlled trial of thymopentin therapy in patients with chronic hepatitis B. 195
Interaction between vitamin D binding protein polymorphisms and vitamin D levels in the prediction of antiviral response in chronic hepatitis C. 194
Interleukin-28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C under real-life conditions 192
Progression to cirrhosis and mortality of chronic hepatiita type B: a cohort study with 25 years follow-up in Italy. 191
Accuracy of VirtualTouch Acoustic Radiation Force Impulse (ARFI) Imaging for the Diagnosis of Cirrhosis during Liver Ultrasonography 189
Post-load insulin resistance does not predict virological response to treatment of chronic hepatitis C patients without the metabolic syndrome. 186
[Infection due to hepatitis B virus and host immune response] 183
HCV gentotype 3 and circulating squamous cell carcinoma antigen (SCCA)-IgM are independently associated with histological features of NASH in HCV infected patients. 183
La regressione della cirrosi epatica: non più un mito. 180
A controlled trial of lymphoblastoid interferon for chronic anti-HBe/HBV-DNA positive hepatitis 179
A multicenter prospective observational study to evaluate factors influencing efficacy, tolerance and compliance to antiviral treatment with interferon and ribavirin in daily clinical practice 177
A long term study of hepatitis G virus coinfection in chronic hepatitis B 176
Autoantibodies during alpha-interferon therapy for chronic hepatitis B 175
Hepatitis C virus genotype and prognosis of compensated cirrhosis type C 174
Effect of hepatitis B and C virus infection on the natural history of compensated cirrhosis: a cohort study of 297 patients. 174
A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C. 174
Interaction between vitamin D binding protein polymorphisms and vitamin D levels in the prediction of antiviral response in chronic hepatitis C. 172
Genetic polymorphysms of vitamin d pathway predict antiviral treatment outcome in slow responder naive patients with chronic hepatitis C 172
Long-term outcome of chronic hepatitis B in caucasian patients: mortality after 25 years 171
A randomized study comparing 48 and 96 weeks peginterferon alfa-2a therapy in genotype D HBeAg negative chronic hepatitis B. 169
TLR4 rs4986790 A>G genetic polymorphisms predict liver fibrosis severity in Caucasian patients with chronic hepatitis C. 169
Consensus interferon (CIFN) in combination with ribavirin (RBV) for naive patients with chronic hepatitis C: a multicenter study 168
Natural history of hepatitis B e antigen positive chronic hepatitis B in italian patients: a 25 years longitudinal study 164
[Relationships between clinico-therapeutic parameters and immunological status in patients with lung cancer] 163
Autonomic dysfunction and hemodynamic derangement in cirrhotic cardiomyopathy 163
Hepcidin suppression relative to iron status in patients with chronic Hepatitits C 162
Hepatocellularcarcinoma in cirrhosis: incidence and risk factors. 162
Malattie autoimmuni del fegato 160
A controlled trial of alpha-2 recombinant interferon for chronic HBeAg positive hepatitis 159
Carriage of the EGF RS4444903 A>G functional polimorphism associates with disease progression in chronic HBV infection. 158
Influence of hepatitis delta virus infection on clinical outcome of compensated cirrhosis type B 157
Insulin resistance is not a relevant predictor of sustained virologic response in chronic hepatitis C patients: results from the Italian hepatitis C cohort study (ITAHECS) collaborative group 157
A survey of clinical toxicity of alfa interferon in 11.241 patients with chronic viral hepatitis 157
Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C 155
Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C 155
A multicenter randomized double-blind placebo-controlled trial of interleukin-2 in chronic hepatitis B 154
A controlled trial of thymopentin therapy in HBV-DNA positive chronic hepatitis B 154
Final report of a consensus interferon (CIFN) plus ribavirin (RBV) study for chronic hepatitis C (CHC) 154
PEG-interferon and ribavirin in HCV-related cirrhotic patients with profound thrombocytopenia. 154
Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C 154
Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily clinical parameters. 154
Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C. 153
Efficacy and safety of consensus interferon (CIFN) plus ribavirin (RBV) for naive patients with chronic hepatitis C (CHC): final report of a pilot study 152
[Presence of HBsAg and IgG on the membrane of hepatic cells in patients with acute and chronic hepatitis] 151
Hepatitis C and cirrhosis 151
Progression to cirrhosis, hepatocellular carcinoma and liver related mortality in chronic hepatitis B patients in Italy. 151
Natural course and prognostic factors of hepatitis B. 150
Natural history of hepatitis B and prognostic factors of disease progression 150
Efficacy of prolonged high dose of interferon (IFN) plus ribavirin in young genotype 1/4 patients with chronic hepatitis C not responding to IFN alone 149
Membrane oxidative damage causes hemolitic anemia during ribavirin therapy for chronic hepatitis C 147
Natural history of hepatitis B virus infection and disease 147
Relationship between HBcAg in serum and liver and HBV replication in patients with HBsAg-positive chronic liver disease 146
A seven-gene signature (Cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C 146
-smooth-muscle actin expression in chronic viral hepatitis before and after interferon therapy 146
Incidenza e fattori di rischio di epatocarcinoma. 145
Host genetics regulates liver fibrosis progression in patients with chronic hepatitis C (CHC) 145
Gestione delle infezioni da virus epatite B secondo le linee guida nazionali ed internazionali. 145
Suppressor cell function in chronic active hepatitis 144
Interferon (IFN) induction followed by prolonged high dose IFN in combination with ribavirin (RBV) for relapsers HCV patients: a randomized controlled multicenter trial 142
Natural history of chronic hepatitis B 141
How to predictic the outcome of chronic hepatitis B 140
Role of membrane oxidative damage in the pathogenesis of hemolitic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection 139
[The side effects associated with the interferon-alpha therapy of chronic viral hepatitis] 138
Serum HBV-DNA in anti-HBe positive patients detected by filter and liquid phase hybridization assays 138
Clinical and virological profiles in patients with multiple hepatitis virus infections. 138
-smooth-muscle actin expression in chronic viral hepatitis before and after interferon therapy 138
Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis 137
Antibody dependent cellular cytotoxicity (ADCC) in acute hepatitis B and in chronic active hepatitis 137
Natural history of chronic hepatitis B virus and Hepatitis delta virus infection and disease 136
Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. 136
Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage 136
Efficacy of consensus interferon (CIFN) plus ribavirin (RBV) as initial treatment for chronic hepatitis C patients: an italian multicentre study 136
TLR4 rs4986790 A>G . genetic polymorphisms predict liver fibrosis severity in Caucasian patients with chronic hepatitis B. 136
Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP) 135
Antifibrogenic effect of combination interferon plus ribavirin treatment in patients with chronic hepatitis C 134
Effectiveness of interferon alfa in caucasian patients with viral compensated cirrhosis 133
Reduced serum hepcidin levels in patients with chronic hepatitis C 133
Antibodies to the RNase H domain of hepatitis B virus P protein are associated with ongoing viral replication 132
Suppressor cell activity in viral and non-viral chronic active hepatitis 132
T and K cell function in acute and chronic hepatitis 132
Heteroimmune and autoimmune reactions to liver cell surface antigens in the pathogenesis of acute and chronic hepatitis 131
IL28B genotype, differential expression of intrahepatis interferon-stimulated genes and response to PEG-IFN and ribavirin therapy in an Italian prospective cohort of genotype 1 hepatitis C patients in “real life”. 131
Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B 130
Changes in serum hepatitis B virus (HBV) DNA positivity in chronic HBV infection: results of a long-term follow-up study of 138 patients 130
Hepatitis B core antigen (HBcAg) in serum of patients with chronic hepatitis B detected by a modified radioimmunoassay 130
Influence of GB virus-C/Hepatitis G Virus infection on the long term course of chronic hepatitis B 130
Cellular immunity to the hepatitis B virion in acute and chronic infection 130
Carriage of the EGF rs4444903 A>G functional polymorphism associates with disease progression in chronic HBV infection. 130
Delayed clearance of serum HBAg in compensated cirrhosis B:relation to interferon alpha therapy and disease prognosis 129
Natural history of hepatitis B 129
HLA-DR expression in liver in human HIV infection 128
Attualità in tema di terapia dell’epatite cronica B. 128
Totale 15.876
Salva come PNG Salva come JPEG
Categoria #
all - tutte 127.609
article - articoli 55.521
book - libri 0
conference - conferenze 60.241
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 11.847
Totale 255.218
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021442 0 0 0 0 0 0 0 0 0 11 356 75
2021/20222.414 148 544 11 39 295 76 110 174 172 75 263 507
2022/20234.650 434 301 540 931 438 1.052 34 288 451 22 114 45
2023/20242.363 102 186 166 361 398 301 62 114 4 33 456 180
2024/20256.028 396 508 45 911 387 83 194 264 1.044 403 422 1.371
2025/202613.753 1.307 709 942 2.155 3.383 1.135 1.623 780 1.066 653 0 0
Totale 41.913